Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,502 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The effect of prior exposure to imatinib on transplant-related mortality.
Deininger M, Schleuning M, Greinix H, Sayer HG, Fischer T, Martinez J, Maziarz R, Olavarria E, Verdonck L, Schaefer K, Boqué C, Faber E, Nagler A, Pogliani E, Russell N, Volin L, Schanz U, Doelken G, Kiehl M, Fauser A, Druker B, Sureda A, Iacobelli S, Brand R, Krahl R, Lange T, Hochhaus A, Gratwohl A, Kolb H, Niederwieser D; European Blood and Marrow Transplantation Group. Deininger M, et al. Among authors: lange t. Haematologica. 2006 Apr;91(4):452-9. Haematologica. 2006. PMID: 16585011
High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy.
Willis SG, Lange T, Demehri S, Otto S, Crossman L, Niederwieser D, Stoffregen EP, McWeeney S, Kovacs I, Park B, Druker BJ, Deininger MW. Willis SG, et al. Among authors: lange t. Blood. 2005 Sep 15;106(6):2128-37. doi: 10.1182/blood-2005-03-1036. Epub 2005 May 24. Blood. 2005. PMID: 15914554 Free article.
A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib.
Ernst T, Gruber FX, Pelz-Ackermann O, Maier J, Pfirrmann M, Müller MC, Mikkola I, Porkka K, Niederwieser D, Hochhaus A, Lange T. Ernst T, et al. Among authors: lange t. Haematologica. 2009 Sep;94(9):1227-35. doi: 10.3324/haematol.2009.006981. Epub 2009 Jul 16. Haematologica. 2009. PMID: 19608684 Free PMC article. Clinical Trial.
A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib.
McWeeney SK, Pemberton LC, Loriaux MM, Vartanian K, Willis SG, Yochum G, Wilmot B, Turpaz Y, Pillai R, Druker BJ, Snead JL, MacPartlin M, O'Brien SG, Melo JV, Lange T, Harrington CA, Deininger MW. McWeeney SK, et al. Among authors: lange t. Blood. 2010 Jan 14;115(2):315-25. doi: 10.1182/blood-2009-03-210732. Epub 2009 Oct 16. Blood. 2010. PMID: 19837975 Free PMC article.
BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib.
Sherbenou DW, Hantschel O, Kaupe I, Willis S, Bumm T, Turaga LP, Lange T, Dao KH, Press RD, Druker BJ, Superti-Furga G, Deininger MW. Sherbenou DW, et al. Among authors: lange t. Blood. 2010 Oct 28;116(17):3278-85. doi: 10.1182/blood-2008-10-183665. Epub 2010 Jun 2. Blood. 2010. PMID: 20519627 Free PMC article.
1,502 results